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Abstract 
Background: Benzodiazepines are commonly prescribed in prisons amidst the controversies surrounding their 
potential role in causing behavioral disinhibition and aggressive behavior and their association with use and traffick-
ing of illicit and addictive substances. The present study aimed to (1) ascertain the relationship between benzodiaz-
epine prescription (including their dosage and duration of use) and aggressive behavior and behavioral disinhibition 
in prison and (2) investigate whether there was an association between benzodiazepine prescription, (including their 
dosage and duration of use) and using and trafficking illicit and addictive substances during imprisonment.
Methods: Data were extracted from the electronic database of an “open” Swiss prison (n = 1206, 1379 measures) 
over a 5-year period (2010–2015). Measures included benzodiazepine prescription, duration of benzodiazepine use 
and mean dosage, and punishable behaviors (physical and verbal aggression, disinhibited but not directly aggressive 
behaviors, property damage or theft, substance-related offenses, and rule transgression). We assessed the relationship 
between benzodiazepine prescription and punishable behaviors after propensity score matching. Logistic regressions 
were also used to test the relationship of benzodiazepine use duration and dosage with punishable behaviors among 
participants who received benzodiazepines.
Results: After propensity score matching, benzodiazepine prescription was not significantly associated with any 
punishable behavior. Among detained persons who took benzodiazepines, there was no significant association of 
dosage and duration of use with offenses involving illicit or addictive substance use or trafficking.
Conclusions: Our study did not empirically support the occurrence of increased aggressive or disinhibited behaviors 
or increased risk of substance abuse in detained persons who received benzodiazepines in prison. This suggests a 
need to reconsider restrictions in prescribing benzodiazepines in the prison setting.
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Introduction
Benzodiazepines (BZD) are one of the most widely 
prescribed drugs in Western, Educated, Industrialized, 
Rich, and Democratic (WEIRD) countries [1–5]. They 
are mainly prescribed to treat sleep disorders, anxiety 
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disorders, epilepsy, and withdrawal from certain sub-
stances. Their use has been widely debated. On the 
one hand, BZD act quickly, are very useful in acute set-
tings, and are generally effective. On the other hand, 
they have been associated with various adverse effects, 
including sedation, psychomotor and cognitive impair-
ment, falls and fractures in the elderly, and dependence 
[6, 7]. In addition, individuals with substance use disor-
ders frequently abuse BZD, which is harmful, especially 
when various illicit drugs and opioids are combined 
with BZD [8]. In view of these problems, most treat-
ment guidelines do not recommend BZD as first-line 
treatment for anxiety and related disorders and suggest 
that they should only be used short-term [9–11]. In 
contrast, several experts have recently pointed out that 
such recommendations are based on little empirical 
evidence and that these guidelines do not adequately 
reflect the risk-to-benefit ratio when using BZD [3, 4, 
12–15].
If use of BZD is controversial in the general population, 
the situation is even more complex in prisons, where 
they are commonly prescribed [16, 17]. First, substance 
use disorders are more common among detained persons 
than in the general population [18], and smuggling and 
trafficking of drugs are frequent in prisons around the 
world [19]. Considering the likelihood of BZD abuse in 
the context of substance use disorders, it has been sug-
gested that BZD should be entirely avoided or minimally 
prescribed in prisons [16, 20–22]. However, this is prob-
lematic, because prisoners would be deprived of a valid 
therapeutic option [2, 23].
Another crucial issue associated with prescribing BZD 
in prisons pertains to an increased risk of behavioral dis-
inhibition, resulting in aggressive behavior [1, 24]. There 
is a dearth of research on this topic [25], and some stud-
ies suggest that the link between BZD use and heightened 
aggression may only apply to short-acting BZD [26]. Fur-
thermore, violent crime was associated with unusually 
high doses of BZD [27], whereas there was no increase in 
impulsive behavior with therapeutic doses of BZD [28]. 
In a recent study, Albrecht et al. [29] concluded that high 
BZD doses were not sufficient to increase the risk of vio-
lence. These disparate findings make it difficult to under-
stand the role of BZD as a treatment option in the prison 
setting.
In view of the aforementioned issues and controver-
sies, the present study, conducted in a sample of Swiss 
detained persons, had two main aims: (1) to ascertain the 
relationship between BZD prescription and aggressive 
behavior and behavioral disinhibition in prison; we also 
aimed to assess the potential effects of the dosage of BZD 
and duration of their use on aggression and behavioral 
inhibition during imprisonment; and (2) to investigate 
whether BZD prescription was associated with using and 
trafficking illicit and addictive substances.
Materials and methods
Study design and participants
This retrospective cohort study was based on the 
data on 1206 persons detained in Realta prison, Kan-
ton  Graubünden, Switzerland. This is an “open” prison 
(capacity of 120) for sentenced males who work outside 
the prison and have up to 36 h of leave per week. Data for 
the 2010–2015 period were extracted from the electronic 
prison database (Gina, Ultrasoft AG®) on 1379 meas-
ures. (Some detained persons were incarcerated multiple 
times.)
Administration of all medications is strictly regulated 
in the Swiss correctional facilities and follows directions 
from the Swiss Centre of Expertise in Prison and Proba-
tion, which supports the Swiss Conference of Cantonal 
Justice and Police Directors. Medications under a con-
trolled prescribing regimen (e.g., BZD) are prescribed by 
the prison medical team and administered in a strictly 
specified manner: Tablets are crushed by nurses, dis-
solved in water, and consumed in the health service 
office under nurses’ supervision. PRN administration of 
BZDs was not allowed and not included in the analyses. 
Detained persons are at not allowed to carry any pre-
scription medication outside the health service office. 
Approval for conducting the study was received from 
the Cantonal Research Ethics Committee of Bern (no. 
2016-01539).
Variables
1. Socio-demographics These include age and region of 
origin.
2. Incarceration and offense variables We recorded the 
length of incarceration (based on the dates of admis-
sion and discharge) and offenses leading to impris-
onment: violence-related offenses (assaults, sexual 
crime, other kinds of violence); property-related 
offenses (theft, robbery, other property offenses); 
substance-related offenses (violation of drug laws); 
and other offenses (arson, justice obstruction, man-
slaughter, trafficking, violation of weapon laws).
3. BZD prescription We recorded whether or not 
detained persons were prescribed BZD during 
imprisonment. For those who received BZD, dura-
tion (in days) of use and dosage (mean dosage 
expressed as mg/day and converted into diazepam 
mg equivalents) of BZD were collected. The list of 
BZD and diazepam mg equivalent conversion guide-
lines are provided in Additional file 1: Table S1.
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4. Other prescribed medications We recorded whether 
detained persons were prescribed other psychotropic 
medications (i.e., antidepressants, antipsychotics, 
methylphenidate, mood stabilizers, or opioid agonists 
[including heroin used for therapeutic purposes]) 
and medications for any somatic (non-psychiatric) 
condition.
5. Punishable behaviors Data on the type and fre-
quency of detained persons’ punishable behaviors 
were collected. These were classified into five cat-
egories: (1) physical and verbal aggression (assaults 
and threats made against others), (2) disinhibited, 
but not directly aggressive behaviors (e.g., slamming 
doors, swearing), (3) property damage or theft, (4) 
substance-related offenses (alcohol or illicit drug use 
or trafficking), and (5) rule transgression (e.g., smok-
ing when not allowed, returning from leave late). We 
made a binary qualification (presence/absence) for 
each category.
Statistical analyses
We first computed descriptive statistics for all variables. 
Then, we tested whether punishable behaviors were asso-
ciated with BZD prescription.
In the first set of analyses, we used a propensity score 
matching to minimize the effect of confounding factors 
and make it possible to compare individuals who received 
BZD with those who did not receive them. This method 
is used to estimate the effect of a treatment when relying 
on observational data and to address the fact that assign-
ment to a treatment is not random. The propensity score 
matching aims to mimic randomization by matching the 
treated and untreated groups on a set of predetermined 
covariables. The propensity score was first derived using 
group assignment (BZD/no BZD prescription) predicted 
by factors that might influence group assignment: age, 
region of origin (Switzerland/outside of Switzerland), 
length of incarceration, type of offense, use of any other 
psychotropic medication, and use of any medication for 
somatic diseases. Outcome variables (punishable behav-
iors) were not included in this first step of the analysis. 
The propensity score was estimated using a probit regres-
sion. Each participant received a continuous propensity 
score, which constituted the conditional probability of 
having a group assignment (BZD/no BZD prescription) 
with given covariates. We then used the propensity score 
to match participants in each group (BZD/no BZD) with 
the nearest neighbor matching (fill Mahalanobis), allow-
ing multiple neighbors in case of identical propensity 
scores. Therefore, participants with the same propen-
sity scores were matched and considered comparable 
on covariates used to derive the propensity score. Again, 
the matching was done without consideration of the out-
come variables. Finally, the association between matched 
groups and punishable behaviors was tested, computing 
the average treatment effect on the treated (ATT, here 
the effect of having BZD/no BZD prescription) for each 
punishable behavior used as outcome (sanctions related 
to physical and verbal aggression, disinhibited, but not 
directly aggressive behaviors, property damage or theft, 
substance-related offenses, and rule transgression). 
Crude and matched associations (before/after propensity 
score matching) are reported. The balancing properties 
of the propensity score were satisfied.
In the second set of analyses that did not involve pro-
pensity score matching, we focused on detained persons 
who received BZD. We computed five logistic regres-
sions, using as predictors mean dosage and duration of 
BZD prescription and the same outcomes as the first set 
of analyses. For all these models, we controlled for age, 
region of origin, length of incarceration, type of offenses, 
use of any other psychotropic medication, and use of any 
medication for somatic diseases.
For the propensity score analysis, we computed sen-
sitivity analyses using other methods to match groups 
(covariate adjustment, inverse probability weighting, and 
stratification). For the second set of analyses, we per-
formed sensitivity analyses by using the maximum BZD 
dosage instead of the mean dosage. We also conducted 
logistic regressions using mean dosage and duration of 
BZD use coded as zero for detained persons without BZD 
prescription. We also controlled for the effect of short- 
versus long-acting BZD. Finally, to take into account data 
clustering, we ran (1) mixed-effect models on the whole 
sample and on the subsample of participants with BZD 
prescription, to see whether there was a difference when 
considering that some measures were nested into par-
ticipants; and (2) the same analyses (including propen-
sity score matching) using the first incarceration of each 
participant. In all cases, the findings were similar to those 
reported in the “Results” section.
Analyses were performed with Stata 15 (propensity 
score estimation: pscore with no imposition of common 
support, propensity matching: psmatch2 with option 
“ties”).
Results
Descriptive statistics are reported in Table  1. The mean 
age of detained persons was 33.1 ± 10.4  years. About a 
third (35.4%) came from Africa and another third (31.4%) 
from Western Europe. The mean duration of incarcera-
tion was 125.1 days.
A total of 293 (21.3%) detained persons were pre-
scribed BZD during their incarceration (mean duration 
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Table 1 Descriptive statistics and bivariate analyses for socio-demographics, incarceration and offense variables, other prescribed 
medications, and punishable behaviors
a Means and standard deviations
b Percentages and n
c There were 165 missing values for the region of origin (12.0%) and 40 missing values for type of offenses (2.9%)
d Reported for participants with BZD prescription (n = 290)
Variables Whole sample (n = 1379) BZD prescription
Yes (n = 293) No (n = 1,086)
Socio-demographics
  Agea 33.1 (10.4) 35.4 (9.8) 32.5 (10.5)
 Region of  originb,c
  Asia 1.2 (17) 0.7 (2) 1.4 (15)
  Eastern Europe/Balkans 11.6 (160) 8.9 (26) 12.3 (134)
  Eastern, Central, and South Africa 4.1 (57) 1.4 (4) 4.9 (53)
  Latin America 1.7 (23) 1.7 (5) 1.7 (18)
  Middle East 6.7 (93) 4.8 (14) 7.3 (79)
  North Africa 19.2 (265) 21.8 (64) 18.5 (201)
  Switzerland 24.4 (337) 37.2 (109) 21.0 (228)
  Western Africa 12.0 (166) 3.1 (9) 14.5 (157)
  Western Europe 7.0 (96) 6.8 (20) 7.0 (76)
  Unknown/unverified 12.0 (165) 13.7 (40) 11.5 (125)
Prison variables
 Length of incarceration (days)a 125.1 (177.4) 157.3 (171.6) 116.4 (178.1)
 Type of  offensec
   Violenceb 13.1 (180) 15.4 (45) 12.4 (135)
   Propertyb 38.7 (533) 54.6 (160) 34.4 (373)
   Substanceb 19.4 (267) 25.3 (74) 17.8 (193)
   Otherb 60.0 (827) 51.2 (150) 62.3 (677)
Medical information
 Benzodiazepine
   Prescriptionb 21.3 (293) – –
  Duration (no. of days)a,d 91.5 (7.0) – –
  Mean daily dosage (mg/Diazepam equivalent)a,d 24.0 (25.0) – –
 Prescription of other psychotropic medications
   Anyb 25.0 (345) 68.3 (200) 13.4 (145)
   Antidepressantb 11.8 (163) 34.5 (101) 5.7 (62)
   Antipsychoticb 15.7 (217) 43.3 (127) 8.3 (90)
   Methylphenidateb 2.9 (27) 7.2 (21) 0.6 (6)
  Mood  stabilizersb 1.5 (21) 3.8 (11) 0.9 (10)
  Opioid  antagonistb 4.9 (68) 16.0 (47) 1.9 (21)
   Otherb 0.9 (13) 3.1 (9) 0.4 (4)
 Any medication for somatic  diseaseb 32.4 (447) 56.3 (165) 26.0 (282)
Punishable behaviors (outcomes)
 Physical and verbal  aggressionb 5.9 (81) 8.5 (25) 5.2 (56)
 Disinhibited but not directly aggressive  behaviorb 4.7 (65) 7.9 (23) 3.9 (42)
 Property damage or  theftb 2.8 (38) 3.8 (11) 2.5 (27)
 Substance-related  offensesb 11.7 (161) 19.1 (56) 9.7 (105)
 Rule  transgressionb 23.4 (323) 31.7 (93) 21.2 (230)
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of BZD use = 91.5 days, mean dosage = 24.0 mg/day diaz-
epam equivalents).
The most common type of punishable behavior was 
rule transgression (323 instances or 23.4% of the total 
sample), followed by substance-related offenses (161; 
11.7%), physical and verbal aggression (81; 5.9%), disin-
hibited, but not directly aggressive behaviors (65; 4.7%), 
and property damage or theft (38; 2.8%).
In the analyses of the unmatched sample, detained 
persons with and without BZD prescription were sig-
nificantly different in terms of the factors included in the 
propensity score and outcomes (left panel of Table  2). 
In the matched sample, there was no significant differ-
ence on any factor included in the propensity score (right 
panel of Table 2). Thus, BZD prescription was not signifi-
cantly associated with any kind of punishable behavior.
With regard to detained persons who were prescribed 
BZD, the mean dosage of BZD was not associated with 
any kind of punishable behavior (Table  3). Duration 
of BZD prescription was significantly associated only 
with disinhibited, but not directly aggressive behaviors 
(p = .011).
Discussion
The main aim of the present study was to investigate the 
effects of BZD prescription on aggressive behaviors and 
behavioral disinhibition in a Swiss prison. When control-
ling for potentially confounding variables, we did not find 
any association between BZD prescription and punish-
able behaviors. This suggests that control variables might 
have captured a previous tendency towards aggressive 
Table 2 Associations of factors and outcomes with BZD prescription in a sample with and without propensity score matching
BZD benzodiazepine
a Means are reported
b Proportions are reported
Sample without propensity score matching Sample with propensity score 
matching
BZD No BZD p BZD No BZD p
n = 293 n = 1086 n = 253 n = 964
Variables included in the propensity score
  Agea 35.59 32.47 < .001 35.59 35.59 .643
 Region of origin (ref. Switzerland)b 0.43 0.24 < .001 0.43 0.46 .532
 Length of incarceration (no. of days)a 158.30 115.37 < .001 158.30 134.51 .122
 Prescription of other psychotropic  medicationsb 0.67 0.14 < .001 0.67 0.67 .925
 Prescription of medication for somatic  diseaseb 0.55 0.25 < .001 0.55 0.54 .789
 Offence:  violenceb 0.15 0.13 .231 0.15 0.14 .616
 Offence:  propertyb 0.53 0.33 < .001 0.53 0.56 .423
 Offence:  substanceb 0.25 0.18 .018 0.25 0.22 .464
 Offence:  otherb 0.52 0.62 .002 0.52 0.53 .722
Punishable behaviors (outcomes)b
 Physical and verbal aggression 0.08 0.05 .084 0.08 0.04 .194
 Disinhibited but not directly aggressive behavior 0.17 0.10 .001 0.17 0.13 .390
 Property damage or theft 0.08 0.04 .001 0.08 0.07 .576
 Substance-related offenses 0.03 0.03 .617 0.03 0.02 .390
 Rule transgression 0.30 0.21 .003 0.30 0.24 .239
Table 3 Association between BZD dosage and duration of use 
and punishable behaviors (n = 290)
Logistic models were adjusted for age, region of origin (Switzerland/not 
Switzerland), length of incarceration, type of offenses, prescription of any 
other psychotropic medication, and prescription of any medication for somatic 
diseases
BZD benzodiazepine, DV dependent variable, IV independent variable




coef. p value coef. p value
Physical and verbal aggression 0.001 .888 0.001 .847
Disinhibited but not directly 
aggressive behavior
− 0.021 .110 0.010 .011
Property damage or theft 0.010 .399 − 0.005 .343
Substance-related offenses 0.003 .611 0.002 .291
Rule transgression 0.008 .171 0.001 .522
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behavior (reflected by the type of offenses) and psychi-
atric disorders associated with aggressiveness or disin-
hibited behaviors (reflected by the prescription of other 
psychotropic medications). This finding is in line with 
studies showing that therapeutic doses of BZD are not 
associated with heightened aggressive behavior [28, 29], 
but it is in contrast to other research that reports an asso-
ciation between use of BZD and aggressive behavior [1, 
24]. Importantly, we also found no association between 
the dosage of BZD and duration of their use and almost 
all kinds of punishable behaviors among detained per-
sons who received BZD.
The only significant association we identified was 
between use of BZD for longer periods of time (assessed 
as a continuous variable, via number of days of pre-
scription) and presence of disinhibited, but not directly 
aggressive behaviors. However, the effect size of this find-
ing was very small: With an increase in the duration of 
BZD use by 1 day, detained persons were 1.01 time more 
likely to exhibit disinhibited, but not directly aggressive 
behaviors.
The second aim of the study was to investigate whether 
BZD prescription was associated with using and traffick-
ing illicit or addictive substances during imprisonment. 
We found that detained persons taking BZD were not 
more likely to commit offenses involving illicit or addic-
tive substance use or trafficking. This did not change 
when we examined the dosage and duration of BZD use. 
This finding has important implications because pre-
scribing BZD in prisons is often avoided on the grounds 
of their presumed greater abuse potential [20, 21].
Our study has also revealed other important findings 
about the use of BZD in the prison setting. The pro-
portion of detained persons who were prescribed BZD 
(21.3%) was by no means negligible. Moreover, when 
compared with detained persons who were not pre-
scribed BZD, those using BZD were also prescribed sig-
nificantly more often all other classes of psychotropic 
agents and medications for general medical conditions. It 
indicates their high need for adequate healthcare.
Following the principle of the equality of care, prison 
populations should benefit from effective and evidence-
based treatments that are available in the community. 
Our study suggests that BZD in the prison setting should 
not be routinely denied and that they should be available 
under a high standard of supervised medication delivery 
[2, 23]. The same applies to other psychotropic medica-
tions, as well as psychological interventions for mental 
disorders. It is important to acknowledge that there are 
very few alternatives to psychotropic medications in the 
prison system [30] and that treatment of many mental 
health issues should not only rely on medications such as 
BZD.
Limitations
This study has a number of limitations. First, it was based 
on associations and was conducted retrospectively, which 
precludes us from making inferences about any causal 
relationship. Second, punishable behaviors recorded 
by the prison administration were the only indicator of 
aggressive and disinhibited behavior, and we had no 
access to any information about punishable behaviors 
that were concealed or undetected. Future studies should 
be conducted prospectively and use instruments for 
assessing irritability, anger, behavioral disinhibition, and 
aggressiveness. Third, our findings are based on a sam-
ple of male detained persons in a Swiss setting and it is 
uncertain to what extent they can be applied to female 
detained persons in another country. Fourth, there were 
no data on psychiatric diagnoses and specific indica-
tions for prescribing BZD, which might have been help-
ful to better understand and contextualize the risk of 
aggressive behavior and disinhibition. Fifth, prescribing 
any medication does not necessarily mean that it will be 
taken as prescribed. However, BZD prescription is highly 
regulated in Swiss prisons and BZD are administered in 
the health service office and consumed under supervi-
sion. This makes us confident that there was a high level 
of adherence to the prescribed type and dose of BZD. 
Another limitation is that the sample size was modest, 
resulting in a relatively small number of detained persons 
with punishable behaviors; consequently, punishable 
behaviors were analyzed as binary outcomes (present/
absent). Further studies would benefit from inclusion of 
a larger number of detained persons. Due to small num-
bers of participants using the specific types of BZD, it 
was not possible to investigate effects of various types of 
BZD separately, resulting in a heterogeneous sample of 
individuals with BZD prescription. Types of BZD may 
have different relationships with aggression, so further 
studies should also investigate these differences, as well 
as the effects of dosage and duration of BZD use. There is 
also a question of the extent to which our findings could 
be generalized to prison populations in other countries 
and settings. Prospective studies of this topic in differ-
ent countries, jurisdictions, and correctional settings are 
needed to confirm our preliminary findings.
Conclusion
Detained persons are a vulnerable population with a high 
burden of psychiatric and general medical morbidity; 
they should receive appropriate, timely and evidence-
based treatment without institutional barriers to treat-
ment access. More specifically, we did not find support 
for the notions that BZD was associated with aggressive 
or disinhibited behavior or risk of substance abuse in 
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detained persons. As with other pharmacological agents, 
BZD should be used carefully and cautiously in the 
prison setting, along with evidence-based psychological 
interventions.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1186/ s12954- 021- 00504-5.
Additional file 1: Table S1. Types of benzodiazepines prescribed and 




SB, VS, IF, AS, AG, RS, and ML made substantial contributions to the study 
conception and data acquisition. SB and KB performed the statistical analyses. 
SB and VS drafted the manuscript. All authors made substantial contribu-
tions in the interpretation of the data and revised the manuscript critically for 
important intellectual content. All authors agreed to be accountable for all 
aspects of the work related to its accuracy and integrity. All authors read and 
approved the final manuscript.
Funding
None.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
Declarations
Ethics approval and consent to participate
Approval for conducting the study was received from the Cantonal Research 




The authors declare that they have no competing interests.
Author details
1 Division of Prison Health, Geneva University Hospitals and University 
of Geneva, Chemin du Petit Bel Air 2, 1226 Thônex, Geneva, Switzerland. 
2 Office of Corrections, Department of Justice and Home Affairs of the Canton 
of Zurich, Zurich, Switzerland. 3 Faculty of Medicine and Health, Sydney Medi-
cal School, Nepean Clinical School, Discipline of Psychiatry, University of Syd-
ney, Sydney, NSW, Australia. 4 Adult Psychiatry Division, Department of Mental 
Health and Psychiatry, Geneva University Hospitals, Geneva, Switzerland. 
5 Department of Forensic Psychiatry, Institute of Forensic Medicine, University 
of Bern, Bern, Switzerland. 6 Psychiatrische Dienste Graubünden (PDGR), Chur, 
Switzerland. 7 Department of Psychiatry and Behavioral Sciences, Montefiore 
Medical Center, Albert Einstein College of Medicine, New York, USA. 8 Depart-
ment of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, 
University of Zurich, Zurich, Switzerland. 
Received: 16 September 2020   Accepted: 9 May 2021
References
 1. Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine 
use and aggressive behaviour: a systematic review. Aust N Z J Psychiatry. 
2014;48:1096–114.
 2. Liebrenz M, Boesch L, Stohler R, Caflisch C. Agonist substitution—a treat-
ment alternative for high-dose benzodiazepine-dependent patients? 
Addiction (Abingdon, England). 2010;105:1870–4.
 3. Starcevic V. No role for benzodiazepines in posttraumatic stress disorder? 
A surplus of certainty despite scarce evidence. Austr Psychiatry Bull R 
Aust N Z Coll Psychiatr. 2017;25:339–41.
 4. Starcevic V. The reappraisal of benzodiazepines in the treatment of anxi-
ety and related disorders. Expert Rev Neurother. 2014;14:1275–86.
 5. Petitjean S, Ladewig D, Meier CR, Amrein R, Wiesbeck GA. Benzodiazepine 
prescribing to the Swiss adult population: results from a national survey 
of community pharmacies. Int Clin Psychopharmacol. 2007;22:292–8.
 6. TaT K, Saastamoinen LK, Tähkäpää S, Tuulio-Henriksson A, Taiminen T, 
Tiihonen J, Airaksinen MS, Hietala J. Long-term use of benzodiazepines: 
definitions, prevalence and usage patterns—a systematic review of regis-
ter-based studies. Eur Psychiatry J Assoc Eur Psychiatr. 2015;30:1037–47.
 7. Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharma-
col. 2014;77:295–301.
 8. Lavie E, Fatséas M, Denis C, Auriacombe M. Benzodiazepine use among 
opiate-dependent subjects in buprenorphine maintenance treat-
ment: correlates of use, abuse and dependence. Drug Alcohol Depend. 
2009;99:338–44.
 9. Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, Rapee R, Wilkins 
G. Royal Australian and New Zealand College of Psychiatrists clinical prac-
tice guidelines for the treatment of panic disorder, social anxiety disorder 
and generalised anxiety disorder. Aust N Z J Psychiatry. 2018;52:1109–72.
 10. Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer 
JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, et al. Evidence-
based pharmacological treatment of anxiety disorders, post-traumatic 
stress disorder and obsessive-compulsive disorder: a revision of the 
2005 guidelines from the British Association for Psychopharmacology. J 
Psychopharmacol (Oxford, England). 2014;28:403–39.
 11. Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, 
Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety 
Disorders Association of Canada/Association Canadienne des troubles, 
McGill U, Antony MM, Bouchard S, et al. Canadian clinical practice guide-
lines for the management of anxiety, posttraumatic stress and obsessive–
compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.
 12. Cosci F, Nardi AE, Starcevic V, Chouinard G, Balon R. Lormetazepam in 
oral solution: a formulation at risk of high-dose use. Intern Emerg Med. 
2019;14:1203–4.
 13. Krystal JH, Stossel S, Krystal AD. Restricting benzodiazepines to short-
term prescription. JAMA Psychiat. 2015;72:734–5.
 14. Nardi AE, Cosci F, Balon R, Weintraub SJ, Freire RC, Krystal JH, Roth T, Sil-
berman EK, Sonino N, Fava GA, et al. The prescription of benzodiazepines 
for panic disorder: time for an evidence-based educational approach. J 
Clin Psychopharmacol. 2018;38:283–5.
 15. Rickels K, Moeller HJ. Benzodiazepines in anxiety disorders: Reassessment 
of usefulness and safety. World J Biol Psychiatry. 2018;20(7):1–5.
 16. Cabelguenne D, Picard C, Lalande L, Jonker J, Sautereau M, Meunier F, 
Zimmer L. Benzodiazepine dose reduction in prisoner patients: 15 years’ 
teamwork between psychiatrists and pharmacists. J Clin Pharm Ther. 
2018;43:807–12.
 17. Elger BS, Goehring C, Revaz SA, Morabia A. Prescription of hypnotics and 
tranquilisers at the Geneva prison’s outpatient service in comparison to 
an urban outpatient medical service. Soz Praventivmed. 2002;47:39–43.
 18. Fazel S, Yoon IA, Hayes AJ. Substance use disorders in prisoners: an 
updated systematic review and meta-regression analysis in recently 
incarcerated men and women. Addiction (Abingdon, England). 
2017;112:1725–39.
 19. Borrey D, Meyer E, Duchateau L, Lambert W, Van Peteghem C, De 
Leenheer AP. Longitudinal study on the prevalence of benzodiazepine 
(mis)use in a prison: importance of the analytical strategy. Addiction. 
2003;98:1427–32.
 20. McKee J, Penn JV, Koranek A. Psychoactive medication misadventuring in 
correctional health care. J Correct Health Care. 2014;20:249–60.
Page 8 of 8Baggio et al. Harm Reduct J           (2021) 18:58 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 21. Pilkinton PD, Pilkinton JC. Prescribing in prison: minimizing psycho-
tropic drug diversion in correctional practice. J Correct Health Care. 
2014;20:95–104.
 22. Reeves R. Guideline, education, and peer comparison to reduce prescrip-
tions of benzodiazepines and low-dose Quetiapine in prison. J Correct 
Health Care. 2012;18:45–52.
 23. Elger BS. Prisoners’ insomnia: to treat or not to treat? Medical decision-
making in places of detention. Med Sci Law. 2008;48:307–16.
 24. Lekka NP, Paschalis C, Papadourakis A, Beratis S. Characteristics of inmates 
receiving prescribed benzodiazepines in a high-security greek prison. 
Compr Psychiatry. 2003;44:409–14.
 25. Watson TM. Prisoners’ access to psychoactive medications: the need for 
research and improved policy. Int J Drug Policy. 2016;29:98–9.
 26. Liebrenz M, Schneider M, Buadze A, Gehring M-T, Dube A, Caflisch C. 
High-dose benzodiazepine users’ perceptions and experiences of antero-
grade amnesia. J Am Acad Psychiatry Law. 2016;44:328–37.
 27. Lundholm L, Haggård U, Möller J, Hallqvist J, Thiblin I. The trigger-
ing effect of alcohol and illicit drugs on violent crime in a remand 
prison population: a case crossover study. Drug Alcohol Depend. 
2013;129:110–5.
 28. Reynolds B, Richards JB, Dassinger M, de Wit H. Therapeutic doses of diaz-
epam do not alter impulsive behavior in humans. Pharmacol Biochem 
Behav. 2004;79:17–24.
 29. Albrecht B, Staiger PK, Best D, Hall K, Nielsen S, Lubman DI, Miller P. 
Benzodiazepine use of community-based violent offenders: a preliminary 
investigation. J Subst Use. 2017;22:295–303.
 30. Bartlett A, Dholakia N, England R, Hales H, Ev H, McGeorge T, Moss B, 
Ovaisi S, Tukmachi E, Patel S. Prison prescribing practice: practitioners’ 
perspectives on why prison is different. Int J Clin Pract. 2014;68:413–7.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
